Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Longeveron
LGVN
Longeveron
High Costs And HLHS Hurdles Will Crimp Prospects, Spark Renewal
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
18 Aug 25
Updated
18 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$3.00
73.0% undervalued
intrinsic discount
18 Aug
US$0.81
Loading
1Y
-65.7%
7D
16.4%
Author's Valuation
US$3.0
73.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$3.0
73.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-52m
30m
2018
2020
2022
2024
2025
2026
2028
Revenue US$29.9m
Earnings US$4.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
67.67%
Biotech revenue growth rate
12.71%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.79%
Calculation
US$4.86m
Earnings '28
x
12.03x
PE Ratio '28
=
US$58.46m
Market Cap '28
US$58.46m
Market Cap '28
/
16.25m
No. shares '28
=
US$3.60
Share Price '28
US$3.60
Share Price '28
Discounted to 2025 @ 6.79% p.a.
=
US$2.95
Fair Value '25
